BeiGene Signs a Supply Agreement with PureTech for LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors
Shots: The companies collaborated to evaluate BeiGene’s tislelizumab (anti-PD-1 immune checkpoint inhibitor) + PureTech’s LYT-200 (mAb targeting galectin-9) in patients with solid tumors associated with […]